Loading
A phase 1/2 trial of Darolutamide in prostate cancer, run by Pathos AI, Inc., now recruiting.
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC is a phase 1/2 interventional study registered as NCT06785636 by Pathos AI, Inc., with 120 participants planned, started 2025-02-07 and due to reach its primary completion in 2028-06-30. Interventions recorded: Pocenbrodib, Pocenbrodib and Darolutamide. Conditions listed: mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostate Cancer. No results are recorded here; the registry entry is the source.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors.
Shares Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.